Genetic

23andMe Launches New Genetic Reports on Common Forms of Cancer

Retrieved on: 
Wednesday, March 6, 2024

The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.

Key Points: 
  • The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.
  • Availability of the breast cancer and prostate cancer PRS reports is based on self-reported birth sex.
  • The PRS models on which the new 23andMe reports are based were developed using the 23andMe database, and further validated using an external database.
  • To learn more about the new 23andMe PRS reports on cancer, and becoming a 23andMe+ Premium member, visit https://www.23andme.com/membership/ .

Prevent Cancer Foundation awards $1 million in new research grants

Retrieved on: 
Wednesday, February 21, 2024

Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.

Key Points: 
  • Alexandria, Va., Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is pleased to announce new funding for ten scientists who are researching cancer prevention and early detection.
  • Read on for more on the 2024 research grantees or access more detailed information on their projects in the researcher database.
  • Having a family history of cancer can affect the age at which cancer screening begins and genetic testing recommendations.
  • To view all past funded research grant and fellowship projects driving these key advancements in cancer prevention and early detection, explore the Prevent Cancer Foundation’s Award Database.

European UPC Court of Appeal Overturns Injunction Impacting NanoString’s CosMx Products, Company to Immediately Resume Sales in 16 EU Countries

Retrieved on: 
Monday, February 26, 2024

The decision allows NanoString to immediately resume sales of all CosMx products in 16 impacted UPC member countries.

Key Points: 
  • The decision allows NanoString to immediately resume sales of all CosMx products in 16 impacted UPC member countries.
  • “We believe that with today’s decision, the tide is turning in favor of NanoString and scientific freedom.
  • NanoString is evaluating its next steps in Germany in light of today’s decision from the UPC and for now the German injunction remains in place.
  • The CosMx SMI platform has been installed at approximately 180 customer sites to date.

NanoMosaic launches AAV gene therapy bioprocessing and manufacturing QC assays for simultaneous capsid & transgene interrogation with high standardization

Retrieved on: 
Wednesday, March 6, 2024

The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.

Key Points: 
  • The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.
  • "The objectives pursued by NanoMosaic are positive steps forward for a space desperate for a fit-for-purpose tool that can be standardized throughout the entire gene therapy development and manufacturing processes.
  • "NanoMosaic is excited to offer a unique solution to a challenging and fast-growing gene therapy market," said Qimin Quan, PhD, co-founder and Chief Scientific Officer.
  • NanoMosaic will feature the platform and unique gene therapy applications in a live broadcast scientific webinar alongside industry leaders on March 26, 2024, hosted by Genetic Engineering News (GEN).

Parkinson's Foundation to Accelerate Research Through Expanded Genetic Testing and Counseling Study

Retrieved on: 
Tuesday, February 6, 2024

NEW YORK and MIAMI, Feb. 6, 2024 /PRNewswire/ -- Through its Global Parkinson's Genetics Program (GP2), Aligning Science Across Parkinson's (ASAP) has awarded the Parkinson's Foundation a grant that will significantly expand its landmark international genetics study, PD GENEration: Mapping the Future of Parkinson's Disease. The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD). ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.

Key Points: 
  • The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD).
  • ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.
  • It is a patient-facing research study," said Parkinson's Foundation Senior Vice President and Chief Scientific Officer James Beck, PhD.
  • Fox Foundation for Parkinson's Research is ASAP's implementation partner and issued the grants on behalf of ASAP and GP2.

Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform

Retrieved on: 
Sunday, January 7, 2024

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, in collaboration with Enable Medicine, a leading provider of AI-powered biological insights, announces the availability of MaxFuse, an advanced algorithm co-developed in the laboratory of Dr. Garry Nolan for integrating multiomic single-cell and spatial datasets*. Dr. Nolan is a co-founder and member of the Board of Directors of Akoya Biosciences.

Key Points: 
  • Dr. Nolan is a co-founder and member of the Board of Directors of Akoya Biosciences.
  • Recent technology advancements have enabled analyses of the proteome, metabolome, transcriptome, and epigenome both spatially and at the single-cell level.
  • “MaxFuse represents a significant advancement in the analytics capabilities needed to maximize the value of data derived from spatial and single-cell technologies.
  • * MaxFuse was developed in collaboration with the laboratories of Nancy Zhang and Zongming Ma at the University of Pennsylvania.

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024

BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.

Key Points: 
  • BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.
  • Dr Girach was Global Head of Ophthalmology at Merck & Co and Vice President, Clinical Development at Alcon Laboratories.
  • Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics NV as its Chief Medical Officer.
  • Aniz Girach, MD., Chief Medical Officer of SpliceBio, commented: "Inherited retinal diseases are a heterogenous group of rare diseases that can lead to severe visual disability and blindness, affecting approximately 5.5 million people worldwide.

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024

BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.

Key Points: 
  • BARCELONA, Spain, Jan. 3, 2024 /PRNewswire/ -- SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the appointment of Aniz Girach, MD as Chief Medical Officer.
  • Dr Girach was Global Head of Ophthalmology at Merck & Co and Vice President, Clinical Development at Alcon Laboratories.
  • Prior to joining SpliceBio, he led the development of genetic therapies for inherited retinal diseases at ProQR Therapeutics NV as its Chief Medical Officer.
  • Aniz Girach, MD., Chief Medical Officer of SpliceBio, commented: "Inherited retinal diseases are a heterogenous group of rare diseases that can lead to severe visual disability and blindness, affecting approximately 5.5 million people worldwide.

United States Regenerative Medicine Market Report 2023-2028: Robust Product Pipeline in Gene Therapies, Cell Therapies, Tissue Engineering Driving Demand - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 29, 2023

The "United States Regenerative Medicine Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Regenerative Medicine Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The increasing adoption of stem cell technology, technological advancements, and a strong product pipeline are driving the demand for regenerative medicine.
  • Strong Product Pipeline: A robust product pipeline in gene therapies, cell therapies, tissue engineering, and more is driving demand for regenerative medicine.
  • Company Profiles: Detailed analysis of the major companies present in the United States Regenerative Medicine Market.

Clean Cooking Alliance and Partners Prioritize Clean Cooking at COP28

Retrieved on: 
Wednesday, December 13, 2023

/PRNewswire-PRWeb/ -- Clean cooking was a prominent topic at the 28th United Nations Climate Change Conference (COP28) in Dubai. The Clean Cooking Alliance (CCA) and partners ensured that clean cooking was at the forefront of discussions around climate change, environmental sustainability, carbon finance, investment, gender equality, food systems, and sustainable cities.

Key Points: 
  • /PRNewswire-PRWeb/ -- Clean cooking was a prominent topic at the 28th United Nations Climate Change Conference (COP28) in Dubai.
  • The Clean Cooking Alliance (CCA) and partners ensured that clean cooking was at the forefront of discussions around climate change, environmental sustainability, carbon finance, investment, gender equality, food systems, and sustainable cities.
  • The new African Clean Cooking Consortium will address the actions required to achieve universal access to clean cooking in Africa, including country-level planning, establishing Delivery Units, developing country programs, and catalyzing investment.
  • The AfDB announced it will allocate up to 20% of its approved annual lending for energy toward clean cooking solutions.